Diuresis, vasodilation, a renal dip and the switch to tablets are traced for one composite heart failure patient by the MN650 Unit 10 case, each drug followed to its last order. Searches like "mn 650 unit 10 assignment example", "mn650 unit 10 sample" and "mn650 unit 10 example" land here.
What a finished MN650 Unit 10 comprehensive pharmacotherapy case looks like
About [2,500] words across six dated sections, one per hospital day plus transfer. Day one gives weight [96] kg against a dry weight near [88], pressure [168/94] mmHg, creatinine [1.3] mg/dL, and the admission regimen: nitroglycerin at [10-200] mcg/min for pulmonary edema and intravenous furosemide at [2.5] times the home oral dose, the high-dose arm of the DOSE trial (Felker and colleagues, NEJM 2011). Day two adds a net fluid goal and potassium and magnesium checks. Day three records a creatinine rise to [1.7] with continued congestion and argues for continuing diuresis rather than stopping. Day four brings in guideline-directed therapy from the 2022 AHA/ACC/HFSA heart failure guideline. The transfer section is a two-column table: intravenous order on the left, oral replacement on the right, with the conversion factor bracketed and sourced.
How a MN650 Unit 10 example is structured
Days organize the case because the course treats acute pharmacotherapy as a sequence in which each decision alters the next patient. Every day uses the same subheads, assessment, change, reason, monitoring, so a marker can trace any drug from its first order to its last. Two decisions receive extended argument. On day three the paper resists the reflex to stop diuresis when creatinine rises, citing Metra and colleagues (2012) on why a modest rise during effective decongestion lacks the prognosis it once seemed to carry, while naming the findings that would change its mind. The transfer section then does the arithmetic this unit's final assessment usually targets: oral furosemide bioavailability is variable and roughly half, so a direct milligram swap would underdose; torsemide is considered for steadier absorption, with TRANSFORM-HF (2023) cited for its finding of no mortality difference. A discharge monitoring line closes the paper.
Admission: two drips with separate jobs
Nitroglycerin reduces preload and afterload for pulmonary edema; furosemide removes volume. Each receives a bracketed range, a target and a stop condition, and nitrate tolerance within [24-48] hours of continuous infusion is noted.
The dose a trial supports
High-dose intravenous furosemide, [2.5] times the oral dose, is justified from the DOSE trial, where bolus and infusion performed similarly. A net output goal of [1-2] liters a day gives the dose a measurable purpose.
Creatinine rises, diuresis continues
A rise to [1.7] with persistent congestion is argued as acceptable. Findings that would change the plan are listed: falling pressure, rising lactate, or a urine output that stops responding to escalation.
Therapy added before discharge
Guideline-directed agents arrive once pressure and perfusion allow: a beta-blocker restarted, an ARNI and a mineralocorticoid antagonist timed to potassium and renal function, and an SGLT2 inhibitor added. Each carries its guideline class of recommendation.
Transfer orders, converted
Every intravenous order is paired with its oral successor. Furosemide conversion uses a bracketed ratio with the bioavailability source, and torsemide is weighed as an alternative. Nitroglycerin simply stops, with a sentence on why no oral nitrate replaces it.
Where marks go in MN650 Unit 10
The transfer table is read most closely. A one-to-one milligram switch from intravenous to oral furosemide, or a conversion with no stated ratio, is the error this unit most often penalizes, because it sends a patient home underdiuresed. Diuresis stopped at the first creatinine rise, with congestion still present, draws a comment, and so does the opposite, diuresis continued with no named limit. Admission drips without targets or stop conditions look unreasoned against the rest of the course. Guideline-directed therapy omitted entirely, or started all at once regardless of pressure and potassium, suggests the day-by-day structure was decorative. Missing electrolyte monitoring during aggressive diuresis costs a safety point. Minor losses go to trial citations with no year, and to a discharge weight never compared with the admission one.
Get a MN650 Unit 10 example written to your instructions
Share the whole Unit 10 case your MN650 section assigned, every day of data if it runs that long, plus the rubric and whatever template the final paper uses. Nothing is charged for a first sample, which generally arrives within 24-48h and follows each drug from first order to transfer, with every intravenous-to-oral conversion shown and sourced.
MN650 Unit 10 questions, answered
Does the final case have to cover every day of the stay?
Only as far as the prompt requires. Many final cases give a few decision points rather than a full stay, and the sample adopts the structure the prompt sets. Organizing by day works well when the case supplies daily data, because it lets a marker trace each drug; with fewer data points, the sample organizes by decision instead.
How detailed should the conversion arithmetic be?
Detailed enough to check. The sample shows the intravenous dose, the bioavailability assumption and its source, the resulting oral dose, and any rounding to an available tablet strength, each bracketed. Showing the steps matters because conversion errors are common, and a marker can only award reasoning set out where it can be followed.
Can the case use a condition other than heart failure?
Yes. Sepsis, gastrointestinal bleeding, diabetic ketoacidosis and many other admissions work in the same format, since each involves drips that become tablets and decisions that change daily. The sample follows the condition the prompt supplies, and the day-by-day structure with a converted transfer table carries over unchanged.